AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

Recently approved xanomeline and trospium chloride (Cobenfy) demonstrated long-term efficacy and safety in patients with ...

Relative to placebo, lumateperone significantly improved MADRS, CGI-S, and QIDS-SR-16 scores by day 43 among patients with MDD.

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...

Gas Networks Ireland has broken ground to mark the commencement of construction for a €32m Central Grid Injection (CGI) facility in ... designed to showcase large scale agricultural biomethane ...

the Clinical Global Impression-Severity (CGI-S) scale at week five and percentage of PANSS responders at week five compared to placebo. Key secondary endpoints were formally tested sequentially in ...

Auditory verbal hallucinations are one of the hallmarks of psychosis, particularly in people with schizophrenia, which affects 24 million people globally. These voices often bully or abuse the ...

but did not comment on whether it will continue to produce it following this scale back. J&J is also currently engaged in arbitration with Merck & Co., which helped to make the shots after being ...